email@email.com
Request a Call
Contact Online
Subscribe |
| Log In
The most widely read newsletter on China's life science industry.
Toggle navigation
Home
Subscribe
Top Stories
Hot Topics
Search
Conferences
Consulting
About Us
Contact Us
You are here:
All Products
Articles
Instant access to selected
ChinaBio® Today
subscriber-only articles.
Browse
All Products
Articles
Viewing
2371 - 2385
of 3630 products
View All
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
Next
Zai Lab Acquires China Rights to GIST Treatment in $205 Million Deal
$5.00
Available
Shanghai's Brii Bio Invests in Artizan; Gains China Rights to Microbiota Treatment for IBD
$5.00
Available
Shanghai GT Apeiron Launches; Partners with AI Drug Discovery Company Excientia
$5.00
Available
CStone to Start Combo Trial of its PD-L1 with Bayer's Stivarga for Gastric Cancer
$5.00
Available
Everest Acquires China Rights to Kidney Disease Treatment in $121 Million Pact
$5.00
Available
Oncologie Completes $80 Million B Round for US-China Oncology Development
$5.00
Available
China to Audit 77 Pharmas after Kangmei Reports $4.4 Billion Fraud
$5.00
Available
RemeGen Announces Positive Results for HER2 ADC in Urothelial Cancer
$5.00
Available
Xynomic Starts US Trial of Abexinostat-Inbruvica Combo for Lymphoma
$5.00
Available
CStone OK'd to Start China Combination Trials of PD-L1 in HCC
$5.00
Available
Ascentage Reports Positive Trial Data for Two Apoptosis Candidates
$5.00
Available
Shanghai's EpimAb Completes $74 Million Series B for Bi-Specific Antibodies
$5.00
Available
BioMarin Approved in China for Very-Rare Disease Treatment
$5.00
Available
Frontage, a US-China CRO, Completes $205 Million Hong Kong IPO
$5.00
Available
Innovent Announces Data on Four China Trials of Approved PD-1 Drug
$5.00
Available